SECOND AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT BETWEEN NANOMERICS LTD. AND VIRPAX PHARMACEUTICALS, INC.Collaboration and License Agreement • August 10th, 2021 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment to the Collaboration and License Agreement (this “Amendment”) is made effective as of 5/5/21 (the “Amendment Effective Date”) between Virpax Pharmaceuticals, Inc. (“Virpax”) and Nanomerics Ltd. (“Nanomerics”). Virpax and Nanomerics are each sometimes referred to herein as a “Party” and, collectively, as the “Parties.”
AMENDMENT NO. 2Collaboration and License Agreement • August 10th, 2021 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 2 (the “Amendment”) to the Collaboration and License Agreement dated April 11th 2019, as amended by the Amendment No 1 dated December 30th 2019 with respect to the PTSD Program, by and between Nanomerics Ltd. (“Nanomerics”) and Virpax Pharmaceuticals, Inc. (“Virpax”) (the “Agreement”), is made effective this day of January 2021 (the “Amendment Effective Date”).
